Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Non Operating Income (2016 - 2025)

Historic Non Operating Income for Ani Pharmaceuticals (ANIP) over the last 14 years, with Q3 2025 value amounting to -$853000.0.

  • Ani Pharmaceuticals' Non Operating Income rose 6635.11% to -$853000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$294000.0, marking a year-over-year increase of 8906.25%. This contributed to the annual value of -$4.0 million for FY2024, which is 243647.8% down from last year.
  • As of Q3 2025, Ani Pharmaceuticals' Non Operating Income stood at -$853000.0, which was up 6635.11% from $1.7 million recorded in Q2 2025.
  • In the past 5 years, Ani Pharmaceuticals' Non Operating Income ranged from a high of $1.7 million in Q2 2025 and a low of -$2.7 million during Q4 2021
  • Moreover, its 5-year median value for Non Operating Income was -$53000.0 (2023), whereas its average is -$356894.7.
  • As far as peak fluctuations go, Ani Pharmaceuticals' Non Operating Income tumbled by 640000.0% in 2024, and later soared by 207613.64% in 2025.
  • Ani Pharmaceuticals' Non Operating Income (Quarter) stood at -$2.7 million in 2021, then surged by 98.44% to -$42000.0 in 2022, then grew by 21.43% to -$33000.0 in 2023, then plummeted by 4075.76% to -$1.4 million in 2024, then surged by 38.1% to -$853000.0 in 2025.
  • Its Non Operating Income was -$853000.0 in Q3 2025, compared to $1.7 million in Q2 2025 and $198000.0 in Q1 2025.